ReviewBMC pediatrics2025
Pediatric NUT carcinoma: a patient series and literature review.
Review in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNuclear protein in testis (NUT) carcinoma (NC) in children is a rare tumor with highly aggressive nature and dismal prognosis.
methodsWe conducted a retrospective analysis of case series towards NC-patients aged 0-18 years treated at the Department of Pediatric Oncology, Sun Yat-sen University Cancer Center between July 2021 and September 2022. The primary end point was to explore the efficacy of therapy. The clinical and pathological characteristics of the patients were also analyzed. The last follow-up date was March 1, 2025.
resultsThe ages of the patients ranged from 8 to 18 years. The tumor sites were head and neck in four patients and vulva in one patient. Three patients underwent upfront surgical resections, followed by chemotherapy(CHT) ± radiotherapy. One patient received neoadjuvant chemotherapy followed by delayed resection and one patient with inoperable NC received chemotherapy only. BRD4-NUT fusion was positive in 3 patients. No recurrence occurred in two patients receiving postoperative chemotherapy, whereas the response was poor in two patients who could not be initially operated on. Currently, two patients are alive, while one patient died of postoperative infection.
conclusionsNC is a rare and aggressive disease. Local therapy plays a vital role in disease control. NC seems to be sensitive to alkylating agents, platin compounds, and anthracyclines in combination. Multimodal approach including surgery, radiation, multidrug chemotherapy, and PD1 inhibitors may lead to improved outcomes for patients with NC. Novel therapies such as inhibitors of BET proteins, histone deacetylase, EZH2 warrant further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.